Quick Answer
Vicapsys Life Sciences, Inc. reported Research And Development Expense of $15.3 thousand for the year ending 2023.
- Vicapsys Life Sciences, Inc. showed an increase of +16.6% in Research And Development Expense from 2022 to 2023.
- This data is from Vicapsys Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on October 21, 2024.
- XBRL data for this metric is available from 2019 to 2023 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $99.0 thousand | Q1 2020: $94.0 thousand | Q1 2021: $2.3 thousand | Q2 2021: $4.9 thousand | Q1 2022: $10.0 thousand | Q3 2022: $3.1 thousand | Q1 2023: $10.0 thousand | Q2 2023: $2.0 thousand | Q3 2023: $3.3 thousand | Q1 2024: $344.00 | Q2 2024: $10.0 thousand | Q3 2024: $3.7 thousand.
- Over the full 5 years of available data (2019 to 2023), Vicapsys Life Sciences, Inc.'s Research And Development Expense has declined by 84.6%.
- Historical annual values: Fiscal year 2023: $15.3 thousand | Fiscal year 2022: $13.1 thousand | Fiscal year 2021: $17.7 thousand | Fiscal year 2020: $102.2 thousand | Fiscal year 2019: $99.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: